Supplementary Materials

Supplementary Material for:

Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming

Sebastian Zimmer, Alena Grebe, Siril S. Bakke, Niklas Bode, Bente Halvorsen, Thomas Ulas, Mona Skjelland, Dominic De Nardo, Larisa I. Labzin, Anja Kerksiek, Chris Hempel, Michael T. Heneka, Victoria Hawxhurst, Michael L. Fitzgerald, Jonel Trebicka, Ingemar Björkhem, Jan-Åke Gustafsson, Marit Westerterp, Alan R. Tall, Samuel D. Wright, Terje Espevik, Joachim L. Schultze, Georg Nickenig, Dieter Lütjohann, Eicke Latz*

*Corresponding author. E-mail: eicke.latz{at}uni-bonn.de

Published 6 April 2016, Sci. Transl. Med. 8, 333ra50 (2016)
DOI: 10.1126/scitranslmed.aad6100

This PDF file includes:

  • Materials and Methods
  • Fig. S1. CD treatment does not influence general cardiovascular parameters.
  • Fig. S2. CD treatment does not alter plasma sterol concentrations in atherosclerosis regression trials.
  • Fig. S3. CD (10 mM) does not affect the viability of murine macrophages.
  • Fig. S4. CD mediates intracellular CC dissolution.
  • Fig. S5. CC loading of macrophages induces lipid droplet accumulation.
  • Fig. S6. CD does not affect Cyp27a1 expression.
  • Fig. S7. CD treatment induces the expression of cholesterol efflux transporters in aortic arches of atherosclerotic mice.
  • Fig. S8. CD treatment does not alter murine lipoprotein profiles.
  • Table S1. LXR target gene list for GSEA analysis of BMDMs from wild-type and LXRα−/−β−/− mice.
  • Table S2. LXR target gene list for GSEA analysis of human atherosclerotic plaques.
  • Table S3. List of additional metabolic and regulatory genes (nCounter Panel-Plus).
  • Legend for table S4
  • References (4257)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S4. Original data for all figures (provided as an Excel file).